XOMA Corp. Hits New 52-Week High of $38.48, Reflecting Strong Growth

XOMA Corp., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 38.48 on September 23, 2025. This achievement marks a notable increase from its 52-week low of USD 18.35, reflecting a robust performance over the past year with a gain of 61.44%. In comparison, the S&P 500 has shown a performance of 17.38% during the same period.
With a market capitalization of USD 427 million, XOMA Corp. operates in a competitive industry where it continues to navigate its financial landscape. The company currently has a debt-to-equity ratio of 0.33, indicating a manageable level of debt relative to its equity. However, it is important to note that XOMA Corp. is currently loss-making, as reflected by its negative return on equity of -27.82%. The stock does not offer a dividend yield, aligning with its growth-focused strategy. As XOMA Corp. continues to evolve, its recent price movement underscores its current market position and performance metrics.